Xilio Therapeutics, Inc. develops masked immuno-oncology therapies for people living with cancer. Company news centers on its proprietary masking technology, which is designed to localize anti-tumor activity within the tumor microenvironment, and on pipeline updates for masked biologics and multi-specific I-O molecules.
Recurring developments include preclinical data for programs such as XTX601, a masked T cell engager targeting CLDN18.2, updates on XTX501, a bispecific PD-1 / masked IL-2 program, and disclosures involving masked T cell engager programs targeting PSMA and STEAP1. News also covers financial results, scientific conference presentations, inducement equity grants, board composition, and capital-structure actions.
Xilio Therapeutics (Nasdaq: XLO) reported significant advancements in its clinical pipeline and financial results for Q3 2021. The company plans to initiate a Phase 1/2 trial for XTX202, a tumor-selective IL-2, in Q1 2022. After a successful IPO in October 2021, raising approximately $130 million, Xilio is well-positioned to enhance its tumor-selective immuno-oncology therapies. However, net losses increased to $16.3 million from $14.8 million year-over-year. R&D expenses decreased, while G&A expenses rose, reflecting growth in headcount and professional services.
Xilio Therapeutics, Inc. (Nasdaq:XLO) announced promising preclinical results for XTX301, a tumor-selective engineered interleukin-12 (IL-12) candidate, at the Society for Immunotherapy in Cancer’s Annual Meeting. The data demonstrate selective anti-tumor activity with minimal systemic effects, indicating potential for optimized therapeutic index. In animal models, XTX301 achieved up to 90% tumor growth inhibition and showed excellent tolerability in non-human primates. Xilio plans to file an investigational new drug application for XTX301 with the FDA in H2 2022.
Xilio Therapeutics, a biotechnology firm specializing in tumor-selective immuno-oncology therapies, has successfully closed its initial public offering (IPO) of 7,353,000 shares at $16.00 each, raising approximately $117.6 million before expenses. The shares started trading on the Nasdaq under the ticker symbol XLO on October 22, 2021. Underwriters also received an option to purchase up to 1,102,950 additional shares. The company aims to leverage these proceeds to advance its proprietary GPS platform and pipeline of anti-cancer therapies.